Population‐level diagnostic and radiation treatment trends of low‐risk prostate cancer
Cancer · 01.11.2026 · 132 (21)
DOI: 10.1002/cncr.70603 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 26.10.2026. Verfasst von Steven M Monda und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kidney Cancer Research, NCI NIH HHS, BCBSM Value Partnerships Program.
Abstract (Originalsprache)
Background
Overtreatment of low‐risk prostate cancer (PC) undermines screening efforts. Active surveillance is preferred for low‐risk PC, but declining treatment may reflect diagnostic or treatment‐selection changes. We assessed diagnostic risk‐group trends among localized PC and low‐risk trends among radiation‐treated patients since 2010.
Methods
We analyzed localized PC in Surveillance, Epidemiology, and End Results Program (SEER; 2010–2023); Veterans Affairs (VA; 2010–2024); and Michigan Radiation Oncology Quality Consortium (MROQC; 2021–2025). Low‐risk PC was defined as grade group 1, prostate‐specific antigen
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
- VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.
- West Michigan Cancer Center, Kalamazoo, Michigan, USA.
- Covenant HealthCare, Saginaw, Michigan, USA.
- Department of Radiation Oncology, Assarian Cancer Center, Henry Ford Providence Hospital, Novi, Michigan, USA.
ORCID-Profile: William C Jackson, Alex K Bryant, Tudor Borza, Robert T Dess
Förderung
- Kidney Cancer Research
- NCI NIH HHS
- BCBSM Value Partnerships Program
- AHRQ HHS
- Blue Cross Blue Shield of Michigan Foundation
- National Institutes of Health/National Cancer Institute Cancer Biostatistics Training
- National Institutes of Health/National Cancer Institute Advanced Training in Urologic Oncology
- National Cancer Institute
Zitieren
APA
Monda, S. M., Odayar, V., Yin, M., Gonzalez, R. T., Jaime-Casas, S., Hopfensperger, K. M., Kendrick, D., Mietzel, M. A., Mislmani, M., Zaki, M., McLaughlin, P. W., Morgan, T. M., Jackson, W. C., Schipper, M. J., Heimburger, D. K., Bryant, A. K., Pierce, L. J., Borza, T., & Dess, R. T. (2026). Population‐level diagnostic and radiation treatment trends of low‐risk prostate cancer. Cancer, 132(21). https://doi.org/10.1002/cncr.70603
Vancouver
Monda SM, Odayar V, Yin M, Gonzalez RT, Jaime-Casas S, Hopfensperger KM, et al. Population‐level diagnostic and radiation treatment trends of low‐risk prostate cancer. Cancer. 2026;132(21). doi:10.1002/cncr.70603
BibTeX
@article{Monda2026,
author = {Monda, Steven M and Odayar, Varshini and Yin, Maggie and Gonzalez, Rachel Tucker and Jaime-Casas, Salvador and Hopfensperger, Karolyn M and Kendrick, Danielle and Mietzel, Melissa A and Mislmani, Mazen and Zaki, Mark and McLaughlin, Patrick W and Morgan, Todd M and Jackson, William C and Schipper, Matthew J and Heimburger, David K and Bryant, Alex K and Pierce, Lori J and Borza, Tudor and Dess, Robert T},
title = {Population‐level diagnostic and radiation treatment trends of low‐risk prostate cancer},
journal = {Cancer},
year = {2026},
volume = {132},
number = {21},
doi = {10.1002/cncr.70603}
}
EUVIMED